Bruker today announces its collaboration with a community of researchers from European academia and industry as part of the PANACEA project. The aim of the project is to build a trans-national network of multi-disciplinary chemists in need of cutting-edge instrumentation and technical expertise in solid-state nuclear magnetic resonance (NMR). This will enable the development of modern chemistry methods that rely on the analysis of increasingly complex solid substrates in cross-discipline research areas from polymers to pharmaceutical formulations and medical implants.
Launching on September 1st, 2021, PANACEA (cordis.europa.eu) brings together infrastructure and scientists, integrating seven national facilities across Europe and one in the United States. Through Bruker’s support, researchers from the European chemistry community will now have access to some of the best solid-state NMR facilities in the world, which will enable the use of modern solid-state NMR by non-expert users, widening the opportunities for novel applications in chemistry.
In Europe, the chemical industry is one of the largest manufacturing sectors and contributes to 16% of added value in industrial production. Bruker’s participation in the PANACEA consortium will see the company provide best-in-class NMR instrumentation and years of industry expertise to facilitate advances in pharmaceutical, fine chemicals, cosmetics, food, fuel, polymers, and clean energy applications.
By participating in the project, Bruker will support the research community in developing solid-state NMR experimental methodologies that for years have enabled the characterization of structure and dynamics at the atomic level. The focus will be to expand the applicability of dynamic nuclear polarization (DNP)-NMR as well as ultrafast magic angle spinning (MAS) technologies, in solid-state NMR at high and ultrahigh magnetic fields in all disciplines of chemical research and to broaden the user base for these advanced technologies.
Ruediger Weisemann, Senior Director of Scientific Collaborations at Bruker BioSpin, commented: “The ultimate aim of PANACEA and the work of our partners is to give access to cutting edge technology that many within the scientific community could otherwise not reach. PANACEA enables laboratories that don't have high-end, sophisticated equipment to benefit from the large-scale facilities that are the backbone of this project. Our goal is to bring high tech, high value equipment to the entire community and drive further research in the field. Bruker is proud to support the NMR community and to work alongside other collaborators in the project.”
The PANACEA project will run until 2025 and is being coordinated by the Centre National de la Recherche Scientifique (CNRS, France) with participants from the University of Warwick (UK); Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine (Italy); Stichting Katholieke Universiteit (Netherlands); Aarhus Universitet (Denmark); University of Aveiro (Portugal); University of Göteborg (Sweden); Florida State University (United States); Bruker Biospin GmbH (Germany); Mestrelab (Spain); the Weizmann Institute of Science (Israel) and École Polytechnique Fédérale de Lausanne (Switzerland).
Ruediger Weisemann, Senior Director of Scientific Collaborations at Bruker BioSpin
The ultimate aim of PANACEA and the work of our partners is to give access to cutting edge technology that many within the scientific community could otherwise not reach. PANACEA enables laboratories that don't have high-end, sophisticated equipment to benefit from the large-scale facilities that are the backbone of this project. Our goal is to bring high tech, high value equipment to the entire community and drive further research in the field. Bruker is proud to support the NMR community and to work alongside other collaborators in the project.
About Bruker Corporation
Bruker (bruker.com) is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
Ruediger Weisemann - Senior Director of Scientific, Bruker BioSpin Group
P: +49 7243 7695-394 - E: ruediger.weisemann[.]bruker.com.
Sebastian Wegner - Product Manager and Head of Solid State NMR Applications, Bruker BioSpin Group
P: +49 7243 7695082 - E: sebastian.wegner[.]bruker.com.
 2021. 2021 FACTS & FIGURES of the European chemical industry. CEFIC, p.35. Available at: [Accessed 11 August 2021].